Opsoclonus-Myoclonus Syndrome (Kinsbourne Syndrome)

A neurological condition that is characterized by uncontrolled rapid irregular movements of the eye (OPSOCLONUS) and the muscle (MYOCLONUS) causing unsteady, trembling gait. It is also known as dancing eyes-dancing feet syndrome and is often associated with neoplasms, viral infections, or autoimmune disorders involving the nervous system.

Also Known As:

Networked: 146 relevant articles (7 outcomes, 9 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Neuroblastoma
2.	Nervous System Diseases (Neurological Disorders)
3.	Infantile Spasms (West Syndrome)
4.	Seizures (Seizure)
5.	Neoplasms (Cancer)

Experts

1.	Pranzatelli, Michael R: 20 articles (01/2014 - 11/2002)
2.	Tate, Elizabeth D: 20 articles (01/2014 - 11/2002)
3.	Blaes, Franz: 8 articles (12/2015 - 04/2002)
4.	Travelstead, Anna L: 8 articles (06/2012 - 01/2005)
5.	Colliver, Jerry A: 6 articles (05/2013 - 10/2008)
6.	Blaes, F: 6 articles (05/2009 - 11/2003)
7.	Verhulst, Steven J: 5 articles (01/2014 - 01/2010)
8.	Darnell, Robert B: 5 articles (07/2011 - 07/2003)
9.	Kaps, M: 5 articles (05/2009 - 11/2003)
10.	Preissner, Klaus T: 4 articles (12/2015 - 08/2005)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Opsoclonus-Myoclonus Syndrome:

1.	Adrenocorticotropic Hormone (ACTH)FDA Link 06/01/2008 - "Neurometabolic effects of ACTH on free amino compounds in opsoclonus-myoclonus syndrome." 05/01/1998 - "Children with the opsoclonus-myoclonus syndrome (OMS) usually respond to corticotropin (adrenocorticotrophic hormone, ACTH) treatment but the mechanism of benefit is unknown. " 03/01/2013 - "Response to correspondence on "active comparator-controlled, rater-blinded study of corticotropin-based immunotherapies for opsoclonus-myoclonus syndrome"." 02/01/2013 - "A study of immunotherapies in children with opsoclonus-myoclonus syndrome found that treatment combinations were more effective than corticotropin alone. " 07/01/2012 - "Active comparator-controlled, rater-blinded study of corticotropin-based immunotherapies for opsoclonus-myoclonus syndrome."
2.	rituximab (Mabthera)FDA Link 11/01/2007 - "Rituximab has been found to be effective in childhood opsoclonus-myoclonus syndrome. " 06/01/2012 - "We used it to treat a rituximab-allergic child with severe, chronic-relapsing, opsoclonus-myoclonus syndrome (OMS), characterized by persistent cerebrospinal fluid (CSF) B-cell expansion and T-cell dysregulation. " 03/01/2012 - "Response to rituximab in 3 children with opsoclonus-myoclonus syndrome resistant to conventional treatments." 03/01/2011 - "Twenty-five children with opsoclonus-myoclonus syndrome (OMS) received rituximab with or without conventional agents. " 07/01/2010 - "Pediatric dosing of rituximab revisited: serum concentrations in opsoclonus-myoclonus syndrome."
3.	Intravenous Immunoglobulins (IVIG)FDA Link 02/01/2003 - "Parainfectious opsoclonus-myoclonus syndrome: high dose intravenous immunoglobulins are effective." 11/01/2002 - "Forty-one year follow-up of childhood-onset opsoclonus-myoclonus-ataxia: cerebellar atrophy, multiphasic relapses, and response to IVIG." 01/01/2012 - "The childhood PNS, especially the neuroblastoma-associated opsoclonus-myoclonus syndrome also respond to immunosuppressive therapies, plasmapheresis and intravenous immunoglobulins. " 04/01/2002 - "In children with paraneoplastic opsoclonus-myoclonus syndrome, steroids and intravenous immunoglobulins may lead to a complete or partial remission of PNDs." 09/01/2008 - "Rituximab and intravenous immunoglobulins for relapsing postinfectious opsoclonus-myoclonus syndrome."
4.	SteroidsIBA 04/01/2002 - "In children with paraneoplastic opsoclonus-myoclonus syndrome, steroids and intravenous immunoglobulins may lead to a complete or partial remission of PNDs." 11/01/2015 - "Atypical presentation of opsoclonus myoclonus syndrome was suspected and treatment with bolus steroids and immunoglobulin were initiated with some response over 28 months. " 04/01/2014 - "We report a case of opsoclonus myoclonus syndrome attributed to WNV and its clinical course after treatment with a combination of steroids and intravenous immunoglobulin. " 11/01/2005 - "Believed to be autoimmune in origin, opsoclonus-myoclonus syndrome frequently responds to immunomodulatory therapies, such as steroids or intravenous immunoglobulin. " 03/01/2012 - "We report the 1 year follow-up of 3 children affected by non-paraneoplastic Opsoclonus-Myoclonus Syndrome (OMS) resistant to conventional therapies (steroids, ACTH and intravenous immunoglobulins) who were treated with an anti CD20 monoclonal antibody (rituximab). "
5.	Dexamethasone (Maxidex)FDA LinkGeneric 10/01/2006 - "High dose pulsatile dexamethasone therapy in children with opsoclonus-myoclonus syndrome." 03/01/2012 - "Another promising treatment option for neuroblastoma-associated opsoclonus-myoclonus syndrome by oral high-dose dexamethasone pulse: lymphocyte markers as disease activity." 03/01/2008 - "Treatment of neuroblastoma-related opsoclonus-myoclonus-ataxia syndrome with high-dose dexamethasone pulses." 03/01/2012 - "A one-year-old boy with neuroblastoma (NBoma)-associated opsoclonus-myoclonus syndrome (OMS) was treated by oral high-dose dexamethasone (DEX) pulses (20 mg/m(2)/day of DEX for three consecutive days) every 28 days for 6 months after resection of the tumor. " 01/01/2008 - "Chronic relapsing opsoclonus-myoclonus syndrome: combination of cyclophosphamide and dexamethasone pulses."
6.	Clonazepam (Rivotril)FDA LinkGeneric 05/01/2010 - "We present a child with paraneoplastic opsoclonus myoclonus syndrome who responded well to clonazepam. " 05/01/2010 - "Response to clonazepam is an evidence for the involvement of GABAergic neural circuits in the genesis of opsoclonus myoclonus syndrome and is in agreement with fastigial nucleus disinhibition hypothesis." 05/01/2010 - "Clonazepam responsive opsoclonus myoclonus syndrome: additional evidence in favour of fastigial nucleus disinhibition hypothesis?" 06/01/1996 - "Opsoclonus--myoclonus syndrome in an adult: a case report and response to clonazepam."
7.	AntibodiesIBA 05/01/2013 - "A mild form of adult-onset opsoclonus-myoclonus syndrome associated with antiglutamate receptor antibodies--reply." 05/01/2013 - "A mild form of adult-onset opsoclonus-myoclonus syndrome associated with antiglutamate receptor antibodies." 11/01/2012 - "Commentary for "Opsoclonus myoclonus syndrome associated with GQ1b antibodies"." 11/01/2012 - "Opsoclonus myoclonus syndrome associated with GQ1b antibodies." 08/01/2012 - "The purpose was to determine whether GlyR antibodies are found in patients with PERM, ocular flutter syndrome (OFS), and opsoclonus-myoclonus syndrome (OMS). "
8.	gabapentin (Neurontin)FDA LinkGeneric 07/01/2000 - "Opsoclonus-myoclonus syndrome: gabapentin as a new therapeutic proposal." 06/01/2010 - "In this study, 4 patients presenting with locked-in syndrome complicated by opsoclonus-myoclonus syndrome were continuously treated with gabapentin up to 1200 mg/d. " 06/01/2010 - "Opsoclonus-myoclonus syndrome in patients with locked-in syndrome: a therapeutic porthole with gabapentin."
9.	Oligoclonal BandsIBA 07/01/2011 - "In opsoclonus-myoclonus syndrome, cerebrospinal fluid B-cell expansion was demonstrated, but no studies of oligoclonal bands are available. "
10.	ChemokinesIBA 05/01/2013 - "To study the role of Th2-attracting chemokines in opsoclonus-myoclonus syndrome (OMS), a serious neurological paraneoplastic disorder in need of better immunological understanding and therapy. "

Therapies and Procedures

1.	Plasmapheresis 01/01/2001 - "Plasmapheresis as an effective treatment for opsoclonus-myoclonus syndrome." 11/01/2005 - "Delayed, recurrent opsoclonus-myoclonus syndrome responding to plasmapheresis." 11/01/2005 - "This patient did not respond adequately to either agent, so plasmapheresis, a less commonly used modality in opsoclonus-myoclonus syndrome, was attempted. " 11/01/2005 - "Delayed, recurrent opsoclonus-myoclonus syndrome responding to plasmapheresis." 05/01/2004 - "Opsoclonus myoclonus syndrome: response to plasmapheresis."
2.	Combined Modality Therapy 07/01/2014 - "To investigate the efficacy of combined modality therapy for neuroblastoma in children associated with opsoclonus-myoclonus syndrome (OMS-NB). "
3.	Immunotherapy 08/15/2011 - "Full recovery of adult onset opsoclonus myoclonus syndrome after early immunotherapy: a case report." 02/01/2001 - "We analysed a series of 24 adult patients with idiopathic (10 cases) and paraneoplastic (14 cases) opsoclonus-myoclonus syndrome (OMS) to ascertain possible differences in clinical course and response to immunotherapies between both groups. " 03/01/2013 - "Response to correspondence on "active comparator-controlled, rater-blinded study of corticotropin-based immunotherapies for opsoclonus-myoclonus syndrome"." 02/01/2013 - "A study of immunotherapies in children with opsoclonus-myoclonus syndrome found that treatment combinations were more effective than corticotropin alone. " 07/01/2012 - "Active comparator-controlled, rater-blinded study of corticotropin-based immunotherapies for opsoclonus-myoclonus syndrome."
4.	Immunomodulation 03/01/2010 - "A range of immunomodulatory therapies have been advocated for the treatment of Dancing Eye Syndrome/Opsoclonus Myoclonus Syndrome. " 11/01/2005 - "Believed to be autoimmune in origin, opsoclonus-myoclonus syndrome frequently responds to immunomodulatory therapies, such as steroids or intravenous immunoglobulin. "
5.	Aftercare (After-Treatment) 03/01/2009 - "The cerebrospinal fluid and blood immunophenotypes of 15 children with predominantly chronic-relapsing opsoclonus-myoclonus syndrome were compared before and after treatment by flow cytometry. " 04/01/2014 - "We report a case of opsoclonus myoclonus syndrome attributed to WNV and its clinical course after treatment with a combination of steroids and intravenous immunoglobulin. "